RVPH - Reviva Pharmaceuticals GAAP EPS of -$0.25 May, 14 2024 10:50 AM Reviva Pharmaceuticals Holdings Inc. 2024-05-14 10:50:19 ET More on Reviva Pharmaceuticals Reviva reports FDA acceptance of 4-week RECOVER-2 study for its schizophrenia treatment Seeking Alpha’s Quant Rating on Reviva Pharmaceuticals Historical earnings data for Reviva Pharmaceuticals Financial information for Reviva Pharmaceuticals For further details see: Reviva Pharmaceuticals GAAP EPS of -$0.25